Beijing Medical AI Firm Launches RMB 100 Million Biopharma Support Plan
On September 12, 2026, the AI plus healthcare forum of the 2026 China International Fair for Trade in Services was held at Shougang Park in Beijing.
At the forum, China Unicom Beijing Medical Health Large Model Company, known as Jingyi Company, released China's first RMB 100 million biopharmaceutical manufacturing support plan, committing more than RMB 100 million in computing resources to cover the entire industrial chain, including drug discovery, preclinical research and development, and clinical trials.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Pharmaceutical R&D Services, with intensity 60/100 and 70% confidence over a medium term horizon.
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Medium term
Artificial Intelligence
- Direction
- positive
- Intensity
- 55
- Confidence
- 65%
- Horizon
- Medium term
Pharmaceuticals
- Direction
- positive
- Intensity
- 50
- Confidence
- 60%
- Horizon
- Long term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.